BeStock  
Stocks › Biotechnology › VIR

Vir Biotechnology VIR

US equityMarket cap rank #2845Biotechnology
$8.39 −$0.48 (-5.41%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $8.30 -1.05%
Open$8.77
Prev close$8.87
Day range$8.34 – $8.92
Volume3.09M
Market cap$1.56B
P/E (TTM)–
Dividend yield–

VIR Stock News

Headlines matching Vir Biotechnology or the VIR ticker, most recent first.

  • Leerink Partners Maintains Vir Biotechnology(VIR.US) With Buy Rating, Cuts Target Price to $17 NegativeMarket news · 30 Sep 2026 · Direct mention
  • Needham Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $18Market news · 29 Sep 2026 · Direct mention
  • H.C. Wainwright Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $20Market news · 22 Sep 2026 · Direct mention
  • BofA Securities Maintains Vir Biotechnology(VIR.US) With Buy Rating, Cuts Target Price to $15 NegativeMarket news · 8 Aug 2026 · Direct mention
  • A Quick Look at Today's Ratings for Vir Biotechnology(VIR.US), With a Forecast Between $15 to $30Market news · 7 Aug 2026 · Direct mention
  • A Quick Look at Today's Ratings for Vir Biotechnology(VIR.US), With a Forecast Between $18 to $30Market news · 6 Aug 2026 · Direct mention
  • Insiders Of Vir Biotechnology Make A Tidy Sum Selling At US$8.85Simply Wall St · 28 Aug 2026 · Direct mention
  • Analysts Offer Insights on Healthcare Companies: Vir Biotechnology (VIR), Sutro Biopharma (STRO) and Ardent Health Partners, Inc. (ARDT)TipRanks · 11 Jun 2026 · Direct mention
  • Morgan Stanley Maintains Vir Biotechnology(VIR.US) With Buy Rating, Raises Target Price to $27 PositiveMarket news · 11 Jun 2026 · Direct mention
  • Barclays Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $30Market news · 1 Jun 2026 · Direct mention
  • A Quick Look at Today's Ratings for Vir Biotechnology(VIR.US), With a Forecast Between $16 to $30Market news · 8 May 2026 · Direct mention
  • Morgan Stanley Maintains Vir Biotechnology(VIR.US) With Buy Rating, Cuts Target Price to $23 NegativeMarket news · 8 May 2026 · Direct mention
  • Vir Biotechnology | 4: Statement of changes in beneficial ownership of securities-Director Hatfield Jeffrey S.SEC · 29 May 2026 · Direct mention
  • Leerink Partners Maintains Vir Biotechnology(VIR.US) With Buy RatingMarket news · 27 May 2026 · Direct mention
  • BofA Securities Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $16Market news · 14 May 2026 · Direct mention

Discussion

No comments yet — be the first to weigh in on VIR.

Sign in to join the discussion.

Scroll to Top